menu
    • menu
    [{"orgOrder":0,"company":"Pheon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"PHN-010","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Pheon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pheon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pheon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pheon Therapeutics","sponsor":"Brandon Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Series A Financing","leadProduct":"PHN-010","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pheon Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Pheon Therapeutics \/ Brandon Capital","highestDevelopmentStatusID":"5","companyTruncated":"Pheon Therapeutics \/ Brandon Capital"},{"orgOrder":0,"company":"Pheon Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Series B Financing","leadProduct":"PHN-010","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pheon Therapeutics","amount2":0.12,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Pheon Therapeutics \/ TCGX","highestDevelopmentStatusID":"5","companyTruncated":"Pheon Therapeutics \/ TCGX"},{"orgOrder":0,"company":"Pheon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"PHN-012","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Pheon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pheon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pheon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pheon Therapeutics","sponsor":"Biocytogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pheon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pheon Therapeutics \/ Pheon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Pheon Therapeutics \/ Pheon Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Pheon Therapeutics

    Menu

    Pheon Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pheon Therapeutics

                            United Kingdom arrow
                            Global ChemShow
                            Not Confirmed

                            Pheon Therapeutics

                            United Kingdom arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PHN-012

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of PHN-012 in Patients with Advanced Solid Tumors

                            Details : PHN-012 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Colonic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            August 17, 2025

                            Lead Product(s) : PHN-012

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pheon Therapeutics

                            United Kingdom arrow
                            Global ChemShow
                            Not Confirmed

                            Pheon Therapeutics

                            United Kingdom arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PHN-010

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of PHN-010 in Patients With Advanced Solid Tumors

                            Details : PHN-010 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lung Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            June 13, 2024

                            Lead Product(s) : PHN-010

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pheon Therapeutics

                            United Kingdom arrow
                            Global ChemShow
                            Not Confirmed

                            Pheon Therapeutics

                            United Kingdom arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PHN-010

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : TCGX

                            Deal Size : $120.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Pheon Therapeutics Announces $120M Series B Financing for ADC Pipeline Development

                            Details : The financing aims to fund the clinical development of company lead product PHN-010, which is being evaluated in the early-stage trial studies for the treatment of neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            May 21, 2024

                            Lead Product(s) : PHN-010

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : TCGX

                            Deal Size : $120.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pheon Therapeutics

                            United Kingdom arrow
                            Global ChemShow
                            Not Confirmed

                            Pheon Therapeutics

                            United Kingdom arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Biocytogen

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biocytogen Pharmaceuticals Enters into License Agreement with Pheon Therapeutics

                            Details : Under the terms of the agreement, Pheon will develop and commercialize a next generation antibody-drug conjugate (ADC) for a wide range of hard-to-treat cancers developed using Biocytogen’s proprietary RenMiceTM platforms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 05, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Biocytogen

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pheon Therapeutics

                            United Kingdom arrow
                            Global ChemShow
                            Not Confirmed

                            Pheon Therapeutics

                            United Kingdom arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PHN-010

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Brandon Capital

                            Deal Size : $68.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Brandon Capital Co-Leads USD 68M Series A Financing of London-Based ADC Company Pheon Therapeutics

                            Details : The investment will enable Pheon to advance its lead ADC program PHN-010, to clinical proof-of-concept and establish a pipeline of novel ADCs. Pheon’s lead program exploits a novel target that is highly expressed in a broad range of solid tumors.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            September 28, 2022

                            Lead Product(s) : PHN-010

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Brandon Capital

                            Deal Size : $68.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth